Euphas ( Phase II Italian trial ) -> Euphrates phase IIINice story Square !
The real question is how much of an improvement do we see in the Euphrates efficacy over Euphas. Those following along know that Euphas was TERMINATED by the ethics committee for superior efficacy over standard of care ( placebo ) Euphas did NOT screen with Spectral's EAA for patient trial inclusion. Yes, abdominal sugery issues are likely to have patients endotoxin levels elevate, but did Euphas allow low endotoxin level patients to become part of the trial ? I'm always glass "half full", but I have to believe that our phase III could show higher efficacy based on the fact ALL patients have very high endotoxin levels.
Soon we'll know, nice to see Cormark willing to play a ticket or two or 1.1MM+